Agilent Technologies Inc. is pleased to announce that the Agilent NovoCyte Opteon Spectral Flow Cytometer has been awarded the prestigious title of 'Best New Drug Discovery & Development Product of 2024' by SelectScience in the Scientist’s Choice Awards.

The NovoCyte Opteon Spectral Flow Cytometer was launched at the 37th annual Congress of the International Society for the Advancement of Cytometry (CYTO) in May 2024. It features a number of technical innovations, including up to five lasers and 73 detectors, a proprietary optics design, and advanced electronics, enabling it to deliver data with high resolution and sensitivity. The wide dynamic range for both fluorescence detection, and particle size measurement helps to streamline experimental workflows. On-board temperature control, electronics, and fluidics sensor circuitry provide real-time instrument status monitoring and ensure consistent, reliable data acquisition in different ambient environments.

"The NovoCyte Opteon Spectral Flow Cytometer represents a significant advancement in cell measurement, offering unparalleled resolution and sensitivity. It enables customers to gain deeper insights into biology and cellular processes, advancing scientific research and therapeutic development," said Xiaobo Wang, Vice President and General Manager of the Cell Function and Phenotyping Business at Agilent. "The intuitiveness and simplicity of the NovoCyte software also makes spectral flow cytometry widely accessible to researchers. Receiving this award is testament to our commitment to innovation and excellence in scientific research. We are grateful to our scientific community for their support and validation of our efforts."

Terry Sachlos, Associate Professor at York University, Canada, commented, “We are beyond excited to announce the installation of the first-in-Canada Agilent Technologies NovoCyte Opteon Spectral flow cytometer. This state-of-the-art system has already wowed us with its performance as we successfully ran an 18-colour panel on its 3-laser setup on the first day of operation. The ease of use, flexibility, and sensitivity are truly impressive.”

Sachlos added, “Spectral flow cytometry is a gamechanger for multiparameter marker analysis, and we cannot wait to leverage this technology to delve deeper into stem cell and cancer biology.”

The award recognition comes after a rigorous selection process that involved member-led nominations, and a voting survey conducted among the SelectScience scientific community.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide.

Recent news from Agilent Technologies